» Articles » PMID: 32809957

Timing and Regimen of Puberty Induction in Children with Hypogonadism: a Survey on the Practice in Arab Countries

Overview
Date 2020 Aug 19
PMID 32809957
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives There are some variations in the practice of puberty induction between different regions; however, data from Arab countries are lacking. We aimed to survey the practice of pediatric endocrinologists in Arab countries on the timing and regimen for puberty induction in girls and boys with hypogonadism. Methods An online questionnaire was emailed to physicians registered in the Arab Society for Paediatric Endocrinology and Diabetes. Results In total, 106 replies from 17 countries were received. In non Turner syndrome (TS) girls, puberty was induced by 49.4% of participants at 12-13 years and by 32.5% at  ≥14 years. Ethinyl estradiol and conjugated estrogen were the most popular preparations used (29.7 and 16.6%, respectively). Of the participants, 60% introduce progesterone either at 2-3 years after starting estrogen or following a significant breakthrough bleeding on estrogen. In girls with TS, 84.2% of participants prescribed estrogen to those aged 11 years and older (51.5% at 11-12 years) and 5.3% prescribed it to those at the prepubertal age. In boys, 57.3% of participants induce at ≥14 years, 80.6% use intramuscular testosterone and 46.5% start with 50 mg/kg/month. Human chorionic gonadotropin is more used in non-Gulf Arab countries (18.2 vs. 2.9%; p 0.036) with a trend of using oral testosterone undecanoate in Gulf states (12.2 vs. 2.0%; p 0.051). Conclusions We describe the approach to puberty induction in boys and girls among pediatric endocrinologists in Arab countries. The observed variation in practice would be useful in developing regional consensus guidelines on puberty induction in children with hypogonadism.

Citing Articles

Pubertal induction in Turner syndrome without gonadal function: A possibility of earlier, lower-dose estrogen therapy.

Hasegawa Y, Hasegawa T, Satoh M, Ikegawa K, Itonaga T, Mitani-Konno M Front Endocrinol (Lausanne). 2023; 14:1051695.

PMID: 37056677 PMC: 10088859. DOI: 10.3389/fendo.2023.1051695.


Availability and Access to Medications for Puberty Induction and Maintenance in Adolescents with Hypogonadism in the Arab Region.

Deeb A, AlSaffar H, Hamza R, Abass M, Habeb A Int J Clin Pract. 2022; 2022:9142433.

PMID: 35936069 PMC: 9328969. DOI: 10.1155/2022/9142433.


Puberty Induction in Adolescent Males: Current Practice.

Alenazi M, Alqahtani A, Ahmad M, Almalki E, Almutair A, Almalki M Cureus. 2022; 14(4):e23864.

PMID: 35530907 PMC: 9073269. DOI: 10.7759/cureus.23864.


Monitoring Haematocrit in Paediatric Patients Receiving Testosterone Therapy in Arab Countries.

AlSaffar H, Habeb A, Hamza R, Deeb A Cureus. 2021; 13(8):e17618.

PMID: 34646669 PMC: 8483389. DOI: 10.7759/cureus.17618.


Menarche in primary ovarian insufficiency after a month of hormone replacement therapy: a case report.

Cheng B J Med Case Rep. 2021; 15(1):92.

PMID: 33618767 PMC: 7901185. DOI: 10.1186/s13256-020-02603-6.